<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376948</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000495776</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-2005-006</secondary_id>
    <secondary_id>WSU-025806MP4F</secondary_id>
    <nct_id>NCT00376948</nct_id>
  </id_info>
  <brief_title>Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. Genistein may help gemcitabine and erlotinib kill more tumor cells by making tumor&#xD;
      cells more sensitive to the drugs.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving genistein together with gemcitabine&#xD;
      and erlotinib works in treating patients with locally advanced or metastatic pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the 6-month survival rate of patients with locally advanced or metastatic&#xD;
           pancreatic cancer treated with genistein, gemcitabine hydrochloride, and erlotinib&#xD;
           hydrochloride.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the frequency of objective tumor response rate in these patients.&#xD;
&#xD;
        -  Determine the time to treatment failure in these patients.&#xD;
&#xD;
        -  Determine the effect of baseline expression of pAKT and activation of NF-kappaB on&#xD;
           survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall time to disease progression in these patients.&#xD;
&#xD;
        -  Estimate the quantitative and qualitative toxicities of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral genistein twice daily on days -7 to 28 in course 1 and on days 1-28 in&#xD;
      all other courses. Patients also receive gemcitabine hydrochloride IV over 30 minutes on days&#xD;
      1, 8, and 15 and oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every&#xD;
      28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Alive</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Overall Survival Estimate</measure>
    <time_frame>up to 17 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Objective Response Rate (Complete and Partial Response)</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>Imaging tests (CT scan, CXR [Chest X-Ray], MRI or imaging studies as clinically indicated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions. Partial response is defined as greater than or equal to 30% reduction in the sum of the longest diameteres of target lesions, taking as reference the baseline sum of the longest diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Every 8 weeks</time_frame>
    <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or Higher Toxicity Evaluation</measure>
    <time_frame>First day of each cycle</time_frame>
    <description>Toxicity evaluation using NCI-CTC (Common Terminology Criteria) v.3 criteria; CBC (complete blood count) with differential white cell and platelet counts; Serum sodium, potassium, chloride, bicarbonate, AST, ALT, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, and albumin; Serum CA 19-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation</measure>
    <time_frame>At start of study</time_frame>
    <description>Tumor tissue collected from paraffin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Novasoy®, Gemcitabine &amp; Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>genistein</intervention_name>
    <arm_group_label>Novasoy®, Gemcitabine &amp; Erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <arm_group_label>Novasoy®, Gemcitabine &amp; Erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>Novasoy®, Gemcitabine &amp; Erlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
               -  Locally advanced or metastatic disease by radiological evidence&#xD;
&#xD;
          -  Must have biopsy material consisting of 10 unstained slides or paraffin-embedded&#xD;
             tissue blocks available for correlative studies&#xD;
&#xD;
          -  No endocrine tumor or lymphoma of the pancreas&#xD;
&#xD;
          -  No history of CNS (central nervous system) metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  SWOG (Southwest Oncology Group) performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  AST (aspartate aminotransferase) and ALT (alanine aminotransferase) &lt; 1.5 times upper&#xD;
             limit of normal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Albumin &gt; 2.5 g/dL&#xD;
&#xD;
          -  INR (international normalized ratio) &lt; 1.3 (in the absence of ongoing treatment with&#xD;
             warfarin)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No condition that would limit the ability to receive oral medications&#xD;
&#xD;
          -  No requirement for a gastrostomy tube for the administration of drugs&#xD;
&#xD;
          -  No serious concurrent systemic disorder, that, in the opinion of the investigator, is&#xD;
             incompatible with the study&#xD;
&#xD;
          -  No active second primary malignancy within the past year except in situ carcinoma of&#xD;
             the cervix or adequately treated basal cell carcinoma of the skin&#xD;
&#xD;
          -  No allergy to any study drug&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for metastatic disease&#xD;
&#xD;
               -  Prior adjuvant chemotherapy allowed provided it was completed at least 6 months&#xD;
                  ago&#xD;
&#xD;
          -  No prior gemcitabine hydrochloride or epidermal growth factor receptor-inhibiting&#xD;
             agents&#xD;
&#xD;
          -  No other concurrent chemotherapy, immunotherapy, tumor-directed hormonal therapy, or&#xD;
             radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khaldoun Almhanna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fazlul H. Sarkar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <results_first_submitted>August 8, 2014</results_first_submitted>
  <results_first_submitted_qc>August 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2014</results_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
          <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
          <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" lower_limit="39" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Alive</title>
        <time_frame>at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Alive</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Overall Survival Estimate</title>
        <time_frame>up to 17 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival Estimate</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4.6" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Objective Response Rate (Complete and Partial Response)</title>
        <description>Imaging tests (CT scan, CXR [Chest X-Ray], MRI or imaging studies as clinically indicated</description>
        <time_frame>Every 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response Rate (Complete and Partial Response)</title>
          <description>Imaging tests (CT scan, CXR [Chest X-Ray], MRI or imaging studies as clinically indicated</description>
          <units>proportion of patients</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056" lower_limit="0.012" upper_limit="0.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Duration</title>
        <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions. Partial response is defined as greater than or equal to 30% reduction in the sum of the longest diameteres of target lesions, taking as reference the baseline sum of the longest diameters.</description>
        <time_frame>Every 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Response Duration</title>
          <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions. Partial response is defined as greater than or equal to 30% reduction in the sum of the longest diameteres of target lesions, taking as reference the baseline sum of the longest diameters.</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions.</description>
        <time_frame>Every 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="1.74" upper_limit="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions.</description>
        <time_frame>Every 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated). Progressive disesase is defined as a greater than 20% increase in the sum of the longest diameter of target lesions taking as reference the smalles sum of the longest diameter recorded since the treatment started or the appearance of new lesions.</description>
          <units>moths</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" lower_limit="2.04" upper_limit="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Grade 3 or Higher Toxicity Evaluation</title>
        <description>Toxicity evaluation using NCI-CTC (Common Terminology Criteria) v.3 criteria; CBC (complete blood count) with differential white cell and platelet counts; Serum sodium, potassium, chloride, bicarbonate, AST, ALT, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, and albumin; Serum CA 19-9</description>
        <time_frame>First day of each cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 3 or Higher Toxicity Evaluation</title>
          <description>Toxicity evaluation using NCI-CTC (Common Terminology Criteria) v.3 criteria; CBC (complete blood count) with differential white cell and platelet counts; Serum sodium, potassium, chloride, bicarbonate, AST, ALT, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, and albumin; Serum CA 19-9</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neutrophil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>platelet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stomach mucostis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>wbc</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation</title>
        <description>Tumor tissue collected from paraffin</description>
        <time_frame>At start of study</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
            <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
          </group>
        </group_list>
        <measure>
          <title>pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation</title>
          <description>Tumor tissue collected from paraffin</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Novasoy®, Gemcitabine &amp; Erlotinib</title>
          <description>Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, &amp; 15; Erlotinib 150 mg day 1 until day 28&#xD;
genistein&#xD;
erlotinib hydrochloride&#xD;
gemcitabine hydrochloride</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>White blood count (WBC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomach, mucostis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophil</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>WBC (white blood count)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomach, mucositis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was stopped early due to the lack of efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Almhanna Khaldoun, M.D.</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8746</phone>
      <email>almhanna@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

